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photometric methods have been developed and validated for the determination of erythromycin
stearate (ERS) and trimethoprim (TMP) in mixture. In LC method, chromatographic separation
was achieved on a Symmetry Waters C18 column (150 · 4.6 mm, 5 lm) based on isocratic elution
using a mobile phase consisting of potassium dihydrogen phosphate buffer pH (9):acetonitrile:water
(25:100:50, v/v/v) at a ﬂow rate of 1.6 ml min1 with UV detection at 210 nm for ERS and 280 nm
for TMP. Besides, two spectrophotometric methods were applied after reaction with perchloric acid
(12 M) which gives a colored product with ERS. Then, the spectral interference between the colored
product of ERS and TMP was resolved by either ratio spectra derivative spectrophotometry in the
ﬁrst spectrophotometric method or chemometric techniques, namely classical least-squares (CLS),
principal component regression (PCR) and partial least-squares regression (PLS) in the second
spectrophotometric method. The results were statistically compared using one-way analysis of
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82 S.T. Hassib et al.pharmaceutical preparation containing the two drugs and proved to be speciﬁc and accurate for the
quality control of the cited drugs in pharmaceutical dosage forms.
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Erythromycin (ER), (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-
4-[(2,6dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyrano-
syl)oxy]-14-ethyl-7,12,13trihydroxy-3,5,7,9,11,13-hexamethyl-
6-[(3,4,6-trideoxy-3-dimethylamino-b-D-xylo-hexopyranosyl)-
oxy]oxacyclotetradecane-2,10-dione (Fig. 1a) belongs to the
macrolide group of antibiotics while trimethoprim (TMP),
5-(3,4,5-trimethoxybenzyl) pyrimidine-2,4-diamine (Fig. 1b)
is a dihydrofolate reductase inhibitor. The two drugs have
been used in combination as antibacterial compounds.
On literature survey, erythromycin salts and esters have
been determined by several methods including spectrophotom-
etry,1–4 spectroﬂuorometry,5,6 near-infrared spectroscopy,7
high performance liquid chromatography (HPLC).8–19 On
the other hand, trimethoprim has been determined by spectro-
photometry20–24 and high performance liquid chromatography
(HPLC).25,26 Only one article describing the analysis of ERS
and TMP was found but the mixture was not analyzed simul-
taneously. The determination of TMP in the presence of ERS
was accomplished by using zero-crossing ﬁrst derivative (1D),
classical least-squares regression (CLS), and principal compo-
nent regression (PCR) methods. ERS was determined in the
presence of TMP using 2,4-dinitrophenylhydrazine.4 So, it
was effort-worthy to develop analytical methods capable of
determining the two drugs simultaneously.
LC represents an increasing growth that makes it the most
popular method used in pharmaceutical analysis. HPLC
greatly reduces the analysis time and allows for the determina-
tion of many individual components in a mixture using one
single procedure.27 So, it was an intention of this work to ap-
ply the LC technique for the determination of ERS and TMP
in laboratory prepared mixtures and pharmaceutical prepara-
tion containing them.
Besides, due to the ease and availability of different spectro-
photometric instrumentation in pharmaceutical analysis, spec-
trophotometry continues to be very popular, because of its
simplicity and low cost so it has long been applied for the1 Chemical structure of erythanalysis of many drugs.28–37 So, it was intended to apply spec-
trophotometry to the simultaneous determination of ERS and
TMP. ERS reacts with perchloric acid (12 M) to give a colored
product which could be measured at its maximum (482 nm)
without any interference from TMP. On the other hand,
TMP does not react with perchloric acid but its spectrum suf-
fers from an overlap form the spectrum of the colored product
of ERS. So, it was important to develop a method or more to
solve this spectral overlap. In the ﬁrst method, the determina-
tion of TMP is based on the use of the ﬁrst derivative of the
ratio spectra (DR1) to eliminate any spectral interference from
the colored product of ERS.
The second spectrophotometric method comprised the
application of three chemometric techniques namely; classical
least-squares (CLS), inverse least-squares (ILS), principal com-
ponent regression (PCR) and partial least-squares (PLS) to
solve spectral interference between TMP and the colored prod-
uct of ERS after addition of perchloric acid. The main advan-
tages of these techniques are the higher speed of processing
data concerning the values of concentrations and absorbances
of compounds with strongly overlapping spectra. Besides, the
errors of calibration model are minimized by measuring the
absorbance values at many points in the wavelength range of
the zero-order and derivative spectra.
2. Experimental
2.1. Instrumentation
The HPLC (Merck Hitachi) instrument was used; interface
D-7000 equipped with a L-7110 isocratic pump, UV–visible
L-7420 detector, a manual injector equipped with (20 ll) injec-
tor loop and a Xterra C18, 250 · 4.6 mm i.d., 5 lm (Waters,
Ireland) maintained at ambient temperature. Ultrasonic pro-
cessor; GE 130 Fuse size 1.6 A SLO-BLO was used for degas-
sing of the mobile phase.
The Ultraviolet/visible spectrophotometer (Shimadzu UV-
1650 PC, Tokyo, Japan) connected to an IBM compatibleromycin (a) and trimethoprim (b).
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(Shimadzu Corporation, Kyoto, Japan). For the chemometric
method, data analysis was performed using PLS-Toolbox 2.0
running under Matlab, Version 7.
2.2. Reagents and reference samples
Pharmaceutical grade erythromycin stearate containing
99.80% (by microbiological assay),38 trimethoprim containing
99.70% (by non-aqueous titration),39 Erythroprim tablets
(batch number 162077 for the chromatographic method and
batch number 164115 for the two spectrophotometric methods)
nominally containing ERS (equivalent to 250 mg erythromy-
cin) and TMP (80 mg), were supplied by Misr Company for
Pharmaceutical Industries, Cairo, Egypt. Methanol (HiPerSolv
for HPLC), acetonitrile (HiPerSolv), potassium dihydrogen
phosphate (AnalaR) and orthophosphric Acid (85%, AnalaR)
were obtained from VWR Chemicals (Pool, England). Bi-dis-
tilled water was produced in-house (Aquatron Water Still,
A4000D, UK). Membrane ﬁlters 0.45 lm from Teknokroma
(Barcelona, Spain) were used. All other chemicals and reagents
used were of analytical grade unless indicated otherwise. Stan-
dard stock solutions of each drug (1 mg ml1) were prepared by
dissolving 100 mg of the drug in methanol and completing the
volume to 100 ml in a volumetric ﬂask and then the required
concentrations were prepared by serial dilution.
For the LC part, liberation of erythromycin base (ER) from
ERS was carried out to avoid its liberation in any part of the
chromatographic system by the mobile phase. Liberation of
the free base was carried out using the U.S.P method40 as fol-
lows: an accurately weighed 694 mg ERS (equivalent to
500 mg base) was dissolved in 15 ml methanol, then 65 ml
dipotassium acid phosphate buffer (pH 8) was added. The
solution was ﬁltered through a ﬁlter paper into a 100 ml volu-
metric ﬂask, the residue and ﬁlter paper were washed with
methanol (3 · 5 ml) and the extracts were completed to volume
with methanol (5 mg ml1) and then the required concentra-
tions were prepared by serial dilution.
2.3. Chromatographic conditions
Chromatographic separation was achieved on a Symmetry
Waters C18 column (150 · 4.6 mm, 5 lm) based on isocratic
elution using a mobile phase consisting of potassium dihydro-
gen phosphate buffer pH (9):acetonitrile:water (25:100:50,
v/v/v) with UV detection at 210 nm for ERS and 280 nm for
TMP. The buffer solution was ﬁltered through 0.45 lm mem-
brane ﬁlter and degassed for 30 min in an ultrasonic bath prior
to its use. The mobile phase was pumped through the column
at a ﬂow rate of 1.6 ml min1. Analyses were performed at
ambient temperature and the injection volume was 20 ll.
2.4. Sample preparation
2.4.1. For HPLC method
Twenty tablets wereweighed and ﬁnely powdered. A quantity of
the powdered tablets equivalent to (500 mg) ER and (160) mg
TMP was extracted and prepared as shown under Section 2.2.
2.4.2. For the spectrophotometric methods (I and II)
A quantity of the powdered tablets equivalent to (38 mg) ERS
and (8.76 mg) TMP was extracted with methanol (3 · 20 ml)and ﬁltered through a ﬁlter paper into a 100 ml volumetric
ﬂask, the residue and ﬁlter paper were washed with methanol
(3 · 10 ml) and the extracts were completed to volume with
methanol.2.5. General procedures and calibration graphs
2.5.1. For HPLC method
2.5.1.1. Preparation of calibration curves. Accurately measured
aliquots of erythromycin stock solution equivalent to erythro-
mycin (10–30 mg) were transferred into a series of 10 ml volu-
metric ﬂasks and the volumes were completed with methanol.
For TMP, accurately measured aliquots of TMP stock solu-
tion equivalent to (3.2–9.6 mg) were transferred into a series
of 10 ml volumetric ﬂasks and the volumes were completed
with methanol. Twenty microliters of each dilution was
injected and the chromatograms were recorded using the
chromatographic conditions mentioned in Section (2.3).
Calibration curve representing areas under the peaks versus
concentrations in mg ml1 was constructed.
2.5.1.2. Determination of laboratory prepared mixture. Aliquots
from ER and TMP stock solutions equivalent to ER (12.0–
19.5 mg) and TMP (3.52–6.40 mg) were transferred into a ser-
ies of 10 ml volumetric ﬂasks and completed to volume with
methanol then 20 ll of each solution were injected using the
chromatographic conditions mentioned in Section (2.3).
2.5.1.3. HPLC determination of ERS and TMP in Erythroprim
tablets. A quantity of the powdered tablets equivalent to
(500 mg) ER and (160) mg TMP was extracted and prepared
as shown under Section 2.2. Aliquots of this solution equiva-
lent to (10.0–15.0 mg) ER and (3.20–4.80 mg) TMP were intro-
duced into a series of 10 ml volumetric ﬂasks and the volumes
were completed with methanol. The procedure was completed
as under determination of laboratory prepared mixture (Sec-
tion 2.5.1.2.). The experiment was repeated applying the stan-
dard addition technique.2.5.2. For spectrophotometric method I
2.5.2.1. Preparation of calibration curves. Different aliquots
containing (0.15–0.90 mg) and (0.072–0.360 mg) of ERS and
TMP stock solutions, respectively were introduced into two
separate sets of 10 ml volumetric ﬂasks followed by addition
of perchloric acid (12 M) solution (3 ml). The reaction was al-
lowed to proceed for 10 min then the volumes were completed
with methanol. For ERS, The absorbance was measured at
482 nm against reagent blank. The absorbance values were
plotted against concentration. For TMP, the stored spectrum
of TMP was divided by the spectrum of ERS colored product
(60 lg ml1) to obtain the ratio spectra then the ﬁrst derivative
of ratio spectra (DR1) were obtained using the following
instrumental parameters [Dk= 5 nm, scaling factor = 1 and
wavelength range (200–600 nm)]. The amplitude measure-
ments of the trough at 240 nm were plotted against
concentration.
2.5.2.2. Determination of the laboratory prepared mixture. The
previous procedure mentioned was applied to determine ERS
and TMP in laboratory prepared mixture using aliquots equiv-
alent to (0.35–0.75 mg) and (0.096–0.192 mg) of ERS stock
84 S.T. Hassib et al.solution and TMP stock solution, respectively to check the
reproducibility and repeatability of the method.
2.5.2.3. Spectrophotometric method I for the determination of
ERS and TMP in ‘‘Erythroprim’’ tablets. A quantity of the
powdered tablets equivalent to (38 mg) ERS and (8.76 mg)
TMP was extracted with methanol (3 · 20 ml) and ﬁltered
through a ﬁlter paper into a 100 ml volumetric ﬂask, the resi-
due and ﬁlter paper were washed with methanol (3 · 10 ml)
and the extracts were completed to volume with methanol. Ali-
quots of this solution equivalent to (0.532 and 0.570 mg) eryth-
romycin stearate and (0.12264 and 0.1314 mg) trimethoprim
were introduced into two series of 10 ml volumetric ﬂasks.
The experiment was repeated applying the standard addition
technique.
2.5.3. For spectrophotometric method II
2.5.3.1. Construction of the training set. Nine binary mixtures
of ERS and TMP were prepared by placing different volumes
of their stock solutions into a series of 10 ml measuring ﬂasks.
Then, perchloric acid (12 M) solution (3 ml) was added to all
ﬂasks. The reaction mixture was left for 10 min and the vol-
umes were completed with methanol. The absorbances of these
mixtures were measured between 200 and 600 nm at 0.5 nm
intervals against corresponding reagent blank.
2.5.3.2. Pre-processing the data. Reject the regions from 200 to
230 nm and above 505 nm.
2.5.3.3. Constructing the models. For the three techniques, the
absorbance data matrix for the training set concentration
matrix (Table 1) were obtained by the measurement of absor-
bances between 230.0 and 505.0 nm in the intervals with
Dk= 0.5 nm. In these techniques, calibration or regression
was obtained by using the absorbance data matrix and concen-
tration data matrix for prediction of the unknown concentra-
tions of ERS and TMP in their binary mixtures and
pharmaceutical formulations. For CLS method, CLS model
was constructed with non-zero intercept. To build the CLS
model, the computer was fed with the absorbance and concen-
tration matrices for the training set. The calculations to obtain
the K matrix were carried out. For the PCR and PLS models,
the training set absorbance and concentration matrices
together with PLS-toolbox 2.0 software were used for
calculations.Table 1 The concentrations of different mixtures of erythro-
mycin stearate and trimethoprim used in the training set.
Sample
No.
Erythromycin stearate conc.
(lgml1)
Trimethoprim
conc. (lgml1)
1 30 36
2 40 33.6
3 45 12
4 45 31.2
5 60 36
6 75 16.8
7 90 12
8 90 16.8
9 90 31.22.5.3.4. Selection of the optimum number of factors to build the
PCR and PLS models. The cross validation method was used,
leaving out one sample at a time, to select the optimum num-
ber of factors. Given a set of nine calibration samples, PCR
and PLS calibrations were performed, and using this calibra-
tion, the concentration of the sample left out was predicted.
The predicted concentrations were then compared with the
actual concentrations and the root mean square error of cross
validation (RMSECV) was calculated. The maximum number
of factors used to calculate the optimum RMSECV was
selected to be six. Visual inspection was used for selecting
the optimum number of factors. It indicates both of the preci-
sion and accuracy of predictions. It was recalculated upon
addition of each new factor to the PLS and PCR models.
RMSECV ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
PRESS
n
r
where PRESS is the predicted residual error sum of squares
and n is the number of calibration samples.
PRESS ¼
X
Ypred  Ytrue
 2
where Ypred and Ytrue are predicted and true concentrations in
lg ml1, respectively.
2.5.3.5. Construction of the validation set. Different six mix-
tures of ERS and TMP were prepared by transferring different
volumes of their stock solutions into 10 ml volumetric ﬂasks
and the procedure under ‘‘construction of the training set’’
was repeated. The suggested models were applied to these mix-
tures to predict the concentrations of ERS and TMP.
2.5.3.6. Application of the proposed chemometric techniques for
the analysis of ERS and TMP in Erythroprim tablets.Aliquots of
the solution prepared in section [5.2.2.3.] equivalent to (532 and
570 lg) ERS and (122.64 and 131.4 lg) TMP were introduced
into a series of 10 ml volumetric ﬂasks and the procedure under
‘‘construction of the training set’’ was repeated. The spectra of
the prepared solutions were scanned then the developed multi-
variate models, CLS, PCR and PLS were applied to calculate
the concentrations of ERS and TMP. The experiment was re-
peated applying the standard addition technique.3. Results and discussion
3.1. HPLC method
For the separation of the examined drugs, various reversed-
phase columns, isocratic mobile phase systems were attempted.
Different ratios of the aqueous and organic phases were tried.
The ﬁnal mobile phase consisting of water, acetonitrile, dipo-
tassium acid phosphate buffer (pH 9) in a ratio of (50:100:25,
v/v/v) provided good separation and good peak symmetry with
a steady base line. Incomplete resolution of peaks or long elu-
tion time was observed upon using ratios other than that pre-
scribed. Acceptable retention times of the two drugs were
achieved on using a ﬂow rate 1.6 ml min1. Detection was car-
ried out at 210 and 260 nm for ERS and TMP, respectively, at
which high detector sensitivity was achieved. The retention
times were 4.71 and 2.67 min for ERS and TMP, respectively
as presented in Fig. 2.
Figure 2 A typical chromatogram of a mixture of erythromycin
(ER) and trimethoprim (TMP) using water: acetonitrile: dipotas-
sium acid phosphate buffer (pH 9) (50:100:25, v/v/v) as mobile
phase at a ﬂow rate of 1.6 ml min1.
Table 2 System suitability tests for the proposed HPLC
method for the simultaneous determination of erythromycin
and trimethoprim.
Item Erythromycin Trimethoprim
N 1123.83 1649.02
R 4.95
K0 3.71 1.67
R.S.D% of peak areas of six injections 1.85 1.72
Liquid chromatographic and spectrophotometric methods for the determination of erythromycin stearate 853.1.1. System suitability tests
According to USP 2007,40 system suitability tests are an inte-
gral part of liquid chromatographic methods in the course of
optimizing the conditions of the proposed method. SystemTable 3 Results obtained by the proposed HPLC method for the s
Item Erythromycin
Retention time 4.71 min
Wavelength of detection 210 nm
Linearity range 1.0–3.0 mg ml1
Regression equation AUP · 104 = 3.6395
(mgml1)  1.3270
Regression coeﬃcient (r2) 0.9938
Sb 0.166
Sa 0.351
Conﬁdence limit of the slope 3.6395 ± 0.528
Conﬁdence limit of the intercept 1.3270 ± 1.116
Standard error of the estimation 0.262
LOD 0.238
LOQ 0.720
Intra-day %RSD 0.74–1.02
Inter-day %RSD 1.42–2.51
Results:
(1) Drug in laboratory prepared mixture
99.59 ± 0.81
(2) Drug in dosage form 100.59 ± 0.70
(3) Drug added 100.59 ± 0.65suitability tests are used to verify that resolution and reproduc-
ibility were adequate for analysis performed. Different param-
eters affecting the chromatographic separation were studied.
The parameters of these tests are column efﬁciency (number
of theoretical plates), tailing of chromatographic peak, peak
resolution factor, and repeatability as %R.S.D of peak area
for six injections and reproducibility of retention as %R.S.D
of retention time. The results of these tests and their accep-
tance criteria according to USP regulation are listed in Table 2.
3.1.2. Linearity
Linearity was studied for ERS and TMP in binary mixture by
the LC and spectrophotometric method I. A linear relationship
between response studied (area under the peak (AUP) and
component concentration (C) was obtained. The regression
equation for each drug was also computed. In this study, ﬁve
concentrations each was repeated three times. The repeated
runs were genuine and not just repetition for the same read-
ings. This approach will provide information on the variation
in the peak area values between samples of the same concen-
tration. The linearity of the calibration curves was validated
by the high value of correlation coefﬁcient. The analytical data
of the calibration curves including standard deviations for the
slope and intercept (Sb, Sa) are summarized in Table 3.
3.1.3. Accuracy
Accuracy of the results was calculated by % recovery of ﬁve
different concentrations of the laboratory prepared mixture
of the two drugs analyzed by the proposed methods and also
by standard addition technique for tablets. The results
obtained including the mean of the recovery, standard devia-
tion, relative standard deviation are displayed in Table 3.
3.1.4. Precision
The repeatability of HPLC–UV detection method was assessed
by analyzing a mixture containing ERS and TMP (n = 6). The
values of the precision (%R.S.D), inter-day and intra-day
precision (using three different concentrations in triplicates
for three days) are displayed in Table 3.imultaneous determination of erythromycin and trimethoprim.
Trimethoprim
2.67 min
280 nm
0.32–0.96 mg ml1
· concerythromycin AUP · 104 = 54.0733 · conctrimethoprim
(mgml1)  2.3174
0.9969
1.745
1.185
54.0733 ± 5.549
2.3174 ± 3.768
0.883
0.054
0.163
0.63–1.11
0.48–1.09
99.74 ± 0.86
94.36 ± 0.65
99.29 ± 0.98
86 S.T. Hassib et al.3.1.5. Selectivity
Selectivity is the ability of the analytical method to measure
the analyte response in the presence of interferences including
related substances. Selectivity was checked by analyzing ERS
and TMP in laboratory prepared binary mixtures. Good reso-
lution and absence of interference between drugs analyzed is
shown in Fig. 2. Moreover, the proposed methods were
applied to a pharmaceutical formulation containing the two
drugs under study. Moreover, the chromatograms of the sam-
ples were checked for the appearance of any extra peaks. No
chromatographic interference from any of the excipients was
found at the retention times of the examined drugs. These
results demonstrate that there was no interference from other
materials in the pharmaceutical formulations and therefore
conﬁrm the speciﬁcity of the method.
3.1.6. Limit of detection and limit of quantiﬁcation
Limit of detection (LOD) which represents the concentration
of analyte at S/N ratio of 3 and limit of quantiﬁcation
(LOQ) at which S/N is 10 were determined for the proposed
methods and results are given in Table 3. LOD and LOQ were
computed LOD and LOQ were computed based on the stan-
dard deviation of the response and the slope.
3.2. For spectrophotometric methods I and II
3.2.1. Spectrophotometric method I
In the UV absorption spectra of ERS and TMP in methanol at
their nominal concentrations in tablets, ERS spectrum is com-
pletely masked by the spectrum of strongly absorbing TMP
(Fig. 3). So, direct simultaneous determination of the two
drugs in mixture is not feasible. ERS, a weekly absorbing mac-
rolide antibiotic, reacts with perchloric acid to give a colored
product which could be measured at its maximum (482 nm).
In literature, phosphoric acid was used for the determination
of four macrolide antibiotics including erythromycin.3 Being
a stronger acid, perchloric acid was used in the present work
for the analysis of ERS. ERS could be evaluated by measuring
the absorbance at 482 nm without any interference from TMP.Figure 3 Zero order absorption spectra of erythromycin
(0.5 mg/10 ml) (–––––) and of trimethoprim (0.168 mg/10 ml)
(––) in methanol.Optimization of the reaction conditions between ERS and per-
chloric acid were studied. An amount of 3 ml 12 M perchloric
acid was found optimum for the reaction. The reaction was
allowed to proceed for 10 min and was found to be stable
for 90 min. On the other hand, TMP does not react with per-
chloric acid but its spectrum suffers from an overlap form the
spectrum of the colored product of ERS. So the determination
of TMP is based on the use of the ﬁrst derivative of the ratio
spectra (DR1) to eliminate any spectral interference from the
colored product of ERS (Fig. 4).
According to the theory of the ratio-spectra derivative
method,29,30 the absorption spectrum of TMP was divided
by a standard spectrum of ERS product. Then, the 1st deriva-
tive of the ratio-spectra were recorded and the values of the
derivatives were measured at suitably selected wavelengths.
Two troughs at 240 and 303 nm were obtained (Fig. 4). Mea-
surements were carried out at 240 nm as it gave more repro-
ducible results for TMP.
An accurate choice of either standard divisors or working
wavelengths is fundamental for the application of derivative
ratio method. In particular, by increasing or decreasing the
concentration of divisor, the resulting derivative values and,
hence, the slope of lines of regression are proportionately
decreased or increased, with consequent variation of both
sensitivity and linearity range. Several tests were made in a
preliminary investigation by using standard divisors in the con-
centration range from 50 to 80 lg ml1. The best results in
terms of sensitivity, repeatability were found by using
60 lg ml1 of ERS colored product spectrum as the chosen
divisor. The method was reproducible in laboratory preparedFigure 4 The ﬁrst derivative ratio spectra (DR1) of trimethoprim
(12–36 lg ml1) (divisor: 60 lg ml1 erythromycin stearate col-
oured product).
Table 4 Results obtained by the proposed spectrophotometric method I for the determination of erythromycin stearate and
trimethoprim.
Item Erythromycin stearate Trimethoprim
kmax of measurements 482 nm 240 nm
Obedience of Beer’s law 15–90 lg ml1 7.2–36 lg ml1
Regression equation A482 nm = 0.012 · concerythromycin stearate
(lgml1) + 0.1076
DR1trimethoprim = 0.0143 · conctrimethoprim
(lgml1) + 0.0028
Regression coeﬃcient (r2) 0.9968 0.9997
Sb 0.0003 0.0001
Sa 0.017 0.003
Conﬁdence limit of the slope 0.012 ± 0.0007 0.0143 ± 0.0003
Conﬁdence limit of the intercept 0.1076 ± 0.042 0.0028 ± 0.008
Standard error of the estimation 0.019 0.003
Results
(1) Drug in laboratory prepared mixture
99.87 ± 0.87 100.17 ± 0.89
(2) Drug in dosage form 103.43 ± 0.2 97.01 ± 0.06
(3) Drug added 99.87 ± 0.76 99.76 ± 0.74
Figure 6 RMSECV plot of a calibration set prediction using cross validation (partial least squares model).
Table 5 Results obtained by the proposed spectrophotometric method II for the determination of erythromycin stearate and
trimethoprim.
Item Erythromycin stearate Trimethoprim
CLS PCR PLS CLS PCR PLS
(1) Drug in laboratory prepared mixture 99.31 100.07 100.07 99.56 99.43 99.43
(2) Drug in dosage form 103.43 103.98 103.56 96.15 96.17 96.22
(3) Drug added 99.32 99.99 100.37 100.20 100.52 100.54
Figure 5 RMSECV plot of a calibration set prediction using cross validation (principal component regression model).
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obtained for the standard addition indicating good accuracy
of the method (Table 4).3.2.2. Spectrophotometric method II
The wavelength range 230–505 nm in the intervals with 0.5 nm
intervals was chosen as it was providing the greatest amount of
Table 6 Tests of signiﬁcance for the proposed HPLC method for the simultaneous determination of erythromycin and trimethoprim.
Statistical term Erythromycin Trimethoprim
Reference method** HPLC method Reference method*** HPLC method
Mean 100.52 99.59 99.51 99.74
±S.D. 1.44 0.81 1.99 0.86
±S.E. 0.64 0.36 0.89 0.38
%RSD 1.43 0.81 2.00 0.86
n 5 5 5 5
V 2.07 0.66 3.96 0.74
t (*2.306) 1.267 0.238
F (*6.39) 3.136 5.350
* Figures in parentheses are the theoretical t and F values at (p= 0.05).
** B.P. 1998 (microbiological assay).38
*** B.P. 2007 (non-aqueous titration).39
Table 7 Tests of signiﬁcance for the proposed spectrophotometric method for the determination of erythromycin stearate and
trimethoprim.
Statistical term Erythromycin stearate Trimethoprim
Reference method** Spectrophoto-metric
method
Reference method*** Spectrophoto-metric
method
Mean 100.52 99.87 99.51 100.17
±S.D. 1.44 0.87 1.99 0.89
±S.E. 0.64 0.39 0.89 0.40
%RSD 1.43 0.87 2.00 0.89
n 5 5 5 5
V 2.07 0.76 3.96 0.79
t (*2.306) 0.867 0.676
F (*6.39) 2.724 5.013
* Figures in parentheses are the theoretical t and F values at (p= 0.05).
** B.P. 1998 (microbiological assay).38
*** B.P. 2007 (non-aqueous titration).39
Table 8 Tests of signiﬁcance for the proposed chemometric methods for the simultaneous determination of erythromycin stearate and
trimethoprim.
Statistical Term Erythromycin stearate Trimethoprim
Reference
method**
CLS non-zero PCR PLS Reference
method***
CLS non-zero PCR PLS
Mean 100.52 99.31 100.07 100.07 99.51 99.56 99.43 99.43
±S.D. 1.44 0.94 0.63 0.63 1.99 0.85 0.83 0.83
±S.E. 0.64 0.38 0.26 0.26 0.89 0.35 0.34 0.34
%RSD 1.43 0.95 0.63 0.63 2.00 0.85 0.83 0.83
n 5 6 6 6 5 6 6 6
V 2.07 0.88 0.40 0.40 3.96 0.72 0.69 0.69
t (*2.262) 1.626 0.652 0.652 0.052 0.084 0.084
F (*6.26) 2.352 5.175 5.175 5.500 5.739 5.739
* Figures in parentheses are the theoretical t and F values at (p= 0.05).
** B.P. 1998 (microbiological assay).38
*** B.P. 2007 (non-aqueous titration).39
88 S.T. Hassib et al.information about the mixture components. CLS model was
constructed with non-zero intercept. The non-zero intercept
allows an additional degree of freedom when K matrix is cal-
culated. This provides an additional opportunity to adjust
the effects of the extraneous substances.41 Selection of the opti-
mum number of factors for the PCR and PLS techniques was a
very important step before constructing the models. If the
number of factors retained was more than the required, morenoise will be added to the data. On the other hand, if the num-
ber retained was less than the required, meaningful data that
could be necessary for the calibration might be ignored. To
select the number of factors in the PLS and PCR algorithms,
a cross-validation method leaving out one sample at a time41
was employed using calibration set of 9 calibration spectra.
Two factors were found suitable for both PCR and PLS meth-
ods as shown in Figs. 5 and 6.
Liquid chromatographic and spectrophotometric methods for the determination of erythromycin stearate 89The chemometric methods (CLS, PCR and PLS) were ap-
plied successfully to the analysis of ERS and TMP in valida-
tion set and erythroprim tablets. To assess the accuracy of
the method, standard addition technique was carried out.
The results were found satisfactory indicating that the addi-
tives of the tablets did not interfere. The results of validation,
tablets and drug added are presented in Table 5.
3.2.3. Statistical analysis
A statistical analysis of the results obtained by the proposed
methods and the reference methods was carried out by ‘‘SPSS
statistical package version 11’’. The signiﬁcant difference
between groups was tested by one way ANOVA (F-test) at
p= 0.05 as shown in Tables 6–8. The test ascertained that
there was no signiﬁcant difference among the methods.
4. Conclusion
The three proposed methods have the advantages of simplicity,
precision, accuracy and convenience for the separation and
quantiﬁcation and can be employed for the assay of their
respective dosage form. So the proposed methods can be used
for the quality control of the cited drugs in ordinary
laboratories.
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